white → orange2 → yellow3
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
4-AcO-MiPT
4-Acetoxy-N-methyl-N-isopropyltryptamine
Mipracetin, O-Acetylmiprocin
4-AcO-MiPT is a synthetic psychedelic of the tryptamine class.1 It is the acetylated form of 4-HO-MiPT and a higher homolog of 4-AcO-DMT, commonly hypothesized to act primarily as a prodrug for its hydroxylated counterpart, though whether it possesses innate activity of its own remains debated. Very little is known about its human pharmacology or toxicity. It remains relatively uncommon, with minimal history of human use, and is primarily acquired through online research chemical vendors.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~5 mg
Light10-15 mg
Moderate15-20 mg
Strong20-35 mg
Heavy35+ mg
Duration
Onset15-45 minutes
Come Up60-120 minutes
Peak1.5-3 hours
Offset1-2 hours
After Effects2-4 hours
Total4-8 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Effects vary widely by individual, dose, and context.
Physical
Cognitive
The cognitive effects of 4-AcO-MiPT are described by many as extremely relaxing, profound and stoning in style when compared to other commonly used psychedelics such as LSD or 2C-B which tend to be energetic and stimulating.
Enhancement of current mind stateConnectivity of thoughtFeelings of fascination, importance and aweTime distortionOutrospectionDéjà vuRemoval of cultural filterFeelings of predeterminismConceptual thinkingDirect communication with the subconsciousEgo suppression, loss and deathFeelings of interdependent oppositesDelusionsStates of unity and interconnectedness
Visual
Geometry
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of Psilocin, Ayahuasca and 2C-E than LSD or 2C-B. It can be comprehensively described through its variations as intricate in complexity, abstract in form, organic in style, structured in organization, brightly lit and multicoloured in scheme, glossy in shading, soft in edges, large in size, slow in speed, smooth in motion, rounded in corners, unimmersive in depth and consistent in intensity. The visuals have a very 'natural' feel to them and at higher dosages are significantly more likely to result in states of Level 8B visual geometry over Level 8A.
Hallucinatory States
4-AcO-MiPT and its various other forms produce a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics.
Auditory
The auditory effects of 4-AcO-MiPT are common in their occurrence and exhibit a full range of effects.
Adapted from the 4-HO-MiPT subjective effects documentation. 4-AcO-MiPT is the acetylated prodrug of 4-HO-MiPT and is reported to produce an effectively identical experience. Forked from Subjective Effect Documentation by
Josie Kins July 2014.
Josie Kins July 2014.See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
4-AcO-MiPT has demonstrated direct activity at human 5-HT2 receptors in vitro. In calcium-mobilization assays it acted as a high-efficacy 5-HT2A agonist (EC50 43.9 nM; Emax 93.2%), a partial 5-HT2B agonist (EC50 44.7 nM; Emax 49.1%), and a lower-potency partial 5-HT2C agonist (EC50 542 nM; Emax 33.7%). These are functional potency and efficacy values, not binding affinities.2
In mice, 4-AcO-MiPT induced the 5-HT2A-associated head-twitch response with an ED50 of 1.11 mg/kg (2.84 µmol/kg). Its similar molar head-twitch potency to 4-HO-MiPT, despite being less potent in vitro at 5-HT2A, was interpreted by the study authors as consistent with in-vivo deacetylation; the study did not directly measure conversion of 4-AcO-MiPT to 4-HO-MiPT.2
Pharmacokinetics
The available compound-specific study supports a prodrug hypothesis indirectly: acetylation reduced in-vitro 5-HT2A potency, whereas 4-AcO-MiPT and 4-HO-MiPT had similar molar potency in the mouse head-twitch assay. Direct formation of 4-HO-MiPT was not measured, and human bioavailability, metabolic enzymes, plasma kinetics, and elimination half-life remain uncharacterized by this study.2
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Develops almost immediately after ingestion.
Baseline Reset
7 days
Half Tolerance
Approximately 3 days
Cross Tolerance
Serotonergic psychedelics
Harm Potential
Addiction & Dependence
Psychological
Extremely LowNot considered habit-forming; the desire to use typically decreases rather than increases with repeated consumption. Like most classical psychedelics, it demonstrates self-regulating properties.citation needed
History & Culture
4-AcO-MiPT is a synthetic psychedelic tryptaminecitation needed that remains relatively obscure within the broader landscape of psychoactive substances. Unlike many classical psychedelics with decades of documented use, this compound has accumulated very little history of human consumption and…
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
International
4-AcO-MiPT is not listed in the inspected current schedules of the 1971 Convention on Psychotropic Substances; its status under the 1961 and 1988 conventions remains a research gap.
By Country
Illegal4
GermanyIllegal (analog/blanket ban)Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019.12 Production, import with intent to market, administration to others, and trading are criminal offenses.13 Possession is prohibited but not subject to criminal penalties.14 Ordering may be considered incitement to place on the market.
NorwayIllegalForskrift om narkotika (narkotikaforskriften), Narkotikalisten16
Norway's Narkotikalisten expressly lists 4-AcO-MiPT and identifies it as 4-acetoksy-N-metyl-N-isopropyltryptamin. The substance is listed directly in the national narcotics regulation, rather than being recorded here through analogue coverage.
SwedenIllegalLag (1999:42) om förbud mot vissa hälsofarliga varor; Förordning (1999:58) om förbud mot vissa hälsofarliga varor1718
4-AcO-MIPT är uttryckligen upptaget som hälsofarlig vara i bilagan till förordning (1999:58). Lagen (1999:42) förbjuder utan tillstånd bland annat införsel, överlåtelse, framställning, försäljningsutbud och innehav; uppsåtliga överträdelser av de angivna förbuden är straffbelagda.
United KingdomClass AControlled as a Class A substance because it is an ester of 4-HO-MiPT, which falls under the tryptamine catch-all clause of the Misuse of Drugs Act 1971.22 Class A carries the most severe penalties under UK law.citation needed
Controlled / restricted3
FinlandRestrictedNarcotics Act 373/2008, §§ 2, 3 and 5 (as amended by Act 1127/2014); Government Decree 1130/2014, § 1 and annex, as replaced by Government Decree 1101/2025 and amended by Government Decree 650/2026 (effective 10 July 2026); the separate narcotics schedule in Government Decree 543/2008 as amended by Government Decrees 1119/2025 and 651/2026345678
4-AcO-MiPT is expressly scheduled in Finland as a consumer-market-banned psychoactive substance, not merely inferred from an analogue or generic class rule. Decree 1101/2025's replacement list continues to name it, and the later Decree 650/2026 removed only 4-BMC, 2-MMC and NEP. The separate current narcotics schedule does not list 4-AcO-MiPT; accordingly, the specific consumer-market ban applies. Under Narcotics Act section 5(2), the specific consumer-market ban covers manufacture, import, storage, offering for sale and transfer, with statutory research and industrial-use pathways; it does not by its wording impose the narcotics category's general possession/use ban. Other Finnish laws may apply according to the facts of a particular transaction.
JapanControlled SubstanceDesignated as a controlled substance effective March 25, 2015 under Japanese drug control legislation.15
SwitzerlandRestrictedVerordnung des EDI vom 30. Mai 2011 über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (BetmVV-EDI, SR 812.121.11), standing 13 March 2026, Article 1(2)(a)-(b) and Annex 6 Verzeichnis e; enabling framework BetmG (SR 812.121)192021
The exact name 4-AcO-MiPT is not printed in the Annex 6 named-entry sequence, but the binding ordinance expressly extends control to esters of substances listed in Annexes 1–6. 4-HO-MIPT is item 83 in Annex 6, and PubChem identities establish the acetate-versus-ol parent relationship used in applying that clause. Verzeichnis e is the Swiss presumed-narcotic-like-effects category, not Verzeichnis d; the schedule provisions establish controlled status and ester coverage but do not impose a universal possession or penalty rule for every factual scenario.
Not scheduled1
United StatesNot scheduledNot specifically scheduled under the Controlled Substances Act.25 However, it may be considered an analogue of psilocin (4-HO-DMT), a Schedule I substance. Sale for human consumption or possession with intent to ingest could potentially be prosecuted under the Federal Analogue Act.
References
Source Pages
Citations
- Gatch MB, Hoch A, & Carbonaro TM. (2020-12-29). Discriminative Stimulus Effects of Substituted Tryptamines in Rats. ACS Pharmacology & Translational Science, 4(2), 467–471. https://doi.org/10.1021/acsptsci.0c001731
- Klein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, McCorvy JD, & Halberstadt AL. (2020-12-14). Investigation of the Structure–Activity Relationships of Psilocybin Analogues. ACS Pharmacology & Translational Science, 4(2), 533–542. https://doi.org/10.1021/acsptsci.0c001761234
- Government Decree 152/2025 amending the annex to Government Decree 1130/2014, Annex. finlex.fi (n.d.). https://www.finlex.fi/api/media/statute/690146/mainPdf/main.pdf?timestamp=2025-04-09T21%3A00%3A00.000Z1
- Government Decree 1101/2025 amending the annex to Government Decree 1130/2014. finlex.fi (n.d.). https://www.finlex.fi/api/media/statute/894481/mainPdf/main.pdf?timestamp=2025-12-09T09%3A25%3A01.081Z1
- Finnish Government decision STM/2026/79 on amending the annex to Decree 1130/2014, leading to Decree 650/2026. valtioneuvosto.fi (n.d.). https://valtioneuvosto.fi/paatokset/paatos?decisionId=65861
- Act 1127/2014 amending the Finnish Narcotics Act (373/2008), sections 3 and 5. finlex.fi (n.d.). https://finlex.fi/api/media/statute/702487/mainPdf/main.pdf?timestamp=2014-12-18T22%3A00%3A00.000Z1
- Government Decree 1119/2025 amending Government Decree 543/2008, Annexes I, II and IV. finlex.fi (n.d.). https://finlex.fi/api/media/statute/896227/mainPdf/main.pdf1
- Finnish Government decision STM/2026/80 on amending the narcotics schedule, leading to Decree 651/2026. valtioneuvosto.fi (n.d.). https://valtioneuvosto.fi/paatokset/paatos?decisionId=65871
- Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/BJNR261510016.html1
- Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/anlage_1.html1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
1 August 2026
Lyrea · Updated the article
13 July 2026
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 4-AcO-MiPT article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
